Collegium Pharmaceutical, Inc. Gain (Loss) on Extinguishment of Debt
Collegium Pharmaceutical, Inc. (COLL) reported Gain (Loss) on Extinguishment of Debt of -$15.99 million for the 3-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-02-26
- Collegium Pharmaceutical, Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-12-31 was -$15.99M.
- Collegium Pharmaceutical, Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-09-30 was $0.00.
- Collegium Pharmaceutical, Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-06-30 was $0.00.
- Collegium Pharmaceutical, Inc. gain (loss) on extinguishment of debt for the quarter ending 2025-03-31 was $0.00.
- Collegium Pharmaceutical, Inc. gain (loss) on extinguishment of debt for fiscal 2025 was -$15.99M.
- Collegium Pharmaceutical, Inc. gain (loss) on extinguishment of debt for fiscal 2024 was -$11.33M.
- Collegium Pharmaceutical, Inc. gain (loss) on extinguishment of debt for fiscal 2023 was -$23.50M.
- Collegium Pharmaceutical, Inc. gain (loss) on extinguishment of debt for fiscal 2015 was $91.00K.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 3 month as first filed | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | -$15.99M 10-K · filed 2026-02-26 | -$15.99M derived: sum of 2 quarters · filed 2026-02-26 | -$15.99M derived: sum of 3 quarters · filed 2026-02-26 | -$15.99M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $0.00 10-K · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 derived: sum of 4 quarters · filed 2026-02-26 | |
| 2025-06-30 | $0.00 10-K · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | -$4.14M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2025-03-31 | $0.00 10-K · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | -$4.14M derived: sum of 3 quarters · filed 2026-02-26 | -$11.33M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | -$4.14M derived: sum of 2 quarters · filed 2026-02-26 | -$11.33M derived: sum of 3 quarters · filed 2026-02-26 | -$11.33M 10-K · filed 2026-02-26 | |
| 2024-09-30 | -$4.14M 10-K · filed 2026-02-26 | -$11.33M derived: sum of 2 quarters · filed 2026-02-26 | -$11.33M 10-Q · filed 2025-11-06 | -$11.33M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | -$7.18M 10-K · filed 2026-02-26 | -$7.18M 10-Q · filed 2025-08-07 | -$7.18M derived: sum of 3 quarters · filed 2026-02-26 | -$7.18M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $0.00 10-K · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | -$47.01M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | -$47.01M derived: sum of 3 quarters · filed 2026-02-26 | -$23.50M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$47.01M derived: sum of 2 quarters · filed 2024-11-07 | -$23.50M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | -$47.01M derived: 10-Q 6 month − 10-K 3 month · filed 2024-08-08 | -$23.50M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $23.50M 10-K · filed 2025-02-27 | -$23.50M 10-Q · filed 2023-05-04 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $0.00 derived: sum of 2 quarters · filed 2018-03-07 | $0.00 derived: sum of 3 quarters · filed 2018-03-07 | $91.00K 10-K · filed 2018-03-07 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | $0.00 derived: sum of 2 quarters · filed 2016-11-10 | $91.00K 10-Q · filed 2016-11-10 | ||
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | $91.00K 10-Q · filed 2016-08-11 | |||
| 2015-03-31 | $91.00K 10-Q · filed 2016-05-11 | ||||
| 2013-12-31 | -$79.00K 10-K · filed 2016-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |